A combination of ursodeoxycholic acid and Allium sativum prevents liver cirrhosis in cholestatic rats
Cholestasis causes liver cirrhosis due to chronic total obstruction, in which accumulated bile acids induce liver inflammation and fibrosis. Inflammatory conditions are associated with hypoalbuminemia, and changes in albumin levels indicate the patient's clinical condition. Allium sativum h...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bangladesh Society for Microbiology, Immunology, and Advanced Biotechnology
2025-03-01
|
| Series: | Journal of Advanced Biotechnology and Experimental Therapeutics |
| Subjects: | |
| Online Access: | https://www.bsmiab.org/jabet/?mno=216646 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Cholestasis causes liver cirrhosis due to chronic total obstruction, in which accumulated bile acids induce liver inflammation and fibrosis. Inflammatory conditions are associated with hypoalbuminemia, and changes in albumin levels indicate the patient's clinical condition. Allium sativum has anti-inflammatory, antioxidant, and antifibrotic effects against various diseases. Further, ursodeoxycholic acid (UDCA) is one of the few available therapies for cirrhosis. Thus, this study aimed to assess the combination of A. sativum and UDCA as standard therapy in preventing liver cirrhosis and cholestasis. The current study was carried out with 35 male Sprague Dawley rats, which were randomly assigned into healthy, negative, and positive control groups, and three treatments of UDCA and graded doses of A. sativum extract. Biliary duct ligation was used for inducing cholestasis, and the treatment was given for 21 days. Liver cirrhosis was assessed based on Laennec grade by histopathological examination. Albumin levels are measured by examining blood serum. The combination of UDCA and A. sativum extract significantly reduced the degree of liver fibrosis and increased albumin levels in mice with cholestasis (p [ J Adv Biotechnol Exp Ther 2025; 8(1.000): 192-199] |
|---|---|
| ISSN: | 2616-4760 |